S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:SRNE

Sorrento Therapeutics Stock Forecast, Price & News

$5.94
-0.03 (-0.50%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.84
$6.15
50-Day Range
$5.94
$8.25
52-Week Range
$5.70
$17.25
Volume
4.08 million shs
Average Volume
8.92 million shs
Market Capitalization
$1.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.19
30 days | 90 days | 365 days | Advanced Chart
Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Sorrento Therapeutics logo

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Headlines

Sorrento Therapeutics (NASDAQ:SRNE) Reaches New 12-Month Low at $5.72
November 24, 2021 |  americanbankingnews.com
Sorrento Therapeutics (NASDAQ:SRNE) Hits New 1-Year Low at $6.11
November 15, 2021 |  americanbankingnews.com
DYAI: Two New Deals & A Pharma in the Wings
November 11, 2021 |  finance.yahoo.com
Sorrento Awarded California Competes Tax Credit
November 7, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
Employees
502
Year Founded
N/A

Sales & Book Value

Annual Sales
$39.99 million
Book Value
$0.43 per share

Profitability

Net Income
$-298.46 million
Net Margins
-692.36%
Pretax Margin
-687.11%

Debt

Price-To-Earnings

Miscellaneous

Free Float
296,227,000
Market Cap
$1.82 billion
Optionable
Optionable

Company Calendar

Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/18/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

621st out of 1,392 stocks

Biological Products, Except Diagnostic Industry

99th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

Is Sorrento Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics
or view top-rated stocks.

How has Sorrento Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRNE shares have increased by 221.1% and is now trading at $5.94.
View which stocks have been most impacted by COVID-19
.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 18th 2022.
View our earnings forecast for Sorrento Therapeutics
.

What price target have analysts set for SRNE?

3 brokerages have issued 1 year price objectives for Sorrento Therapeutics' stock. Their forecasts range from $25.00 to $35.00. On average, they expect Sorrento Therapeutics' stock price to reach $28.67 in the next year. This suggests a possible upside of 382.6% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Henry H. Ji, Chairman, President & Chief Executive Officer
  • Stephen L Klincewicz, VP-Pharmacovigilance & Clinical Operations
  • Najjam Asghar, Chief Financial & Accounting Officer, SVP
  • Mike A. Royal, Chief Medical Officer
  • Alexis Nahama, Senior Vice President & Head-RTX Program

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.89%), Geode Capital Management LLC (1.65%), Bank of New York Mellon Corp (0.38%), Morgan Stanley (0.28%), Schroder Investment Management Group (0.23%) and Citadel Advisors LLC (0.00%). Company insiders that own Sorrento Therapeutics stock include Kim Janda and Robin L Smith.
View institutional ownership trends for Sorrento Therapeutics
.

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Citadel Advisors LLC, Jane Street Group LLC, Schroder Investment Management Group, Emfo LLC, Credit Suisse AG, Morgan Stanley, and New York State Common Retirement Fund.
View insider buying and selling activity for Sorrento Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, UBS Group AG, State of New Jersey Common Pension Fund D, Bank of New York Mellon Corp, Rafferty Asset Management LLC, SG Americas Securities LLC, and Barclays PLC.
View insider buying and selling activity for Sorrento Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $5.94.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics has a market capitalization of $1.82 billion and generates $39.99 million in revenue each year. The biopharmaceutical company earns $-298.46 million in net income (profit) each year or ($1.23) on an earnings per share basis.

How many employees does Sorrento Therapeutics have?

Sorrento Therapeutics employs 502 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

Where are Sorrento Therapeutics' headquarters?

Sorrento Therapeutics is headquartered at 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at [email protected], or via fax at 858-210-3759.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.